Filings buzz in pharmaceuticals: 22% decrease in robotics mentions in Q1 of 2022
We've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.
By
We've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.
ByWe've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.
ByWe've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.
ByWe've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.
ByWe've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.
ByWe've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.
ByWe've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.
ByFor the fiscal year, the operating cash flow witnessed a 11.1% rise to $8.63bn (JPY1,123.1bn).
Thank you for subscribing to Pharmaceutical Technology